The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 Visningar
• 07/18/23
0
0
Bädda in
administrator
Prenumeranter
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna